Literature DB >> 15034010

Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155).

Anja Fuchs1, Marina Cella, Emanuele Giurisato, Andrey S Shaw, Marco Colonna.   

Abstract

The poliovirus receptor (PVR) belongs to a large family of Ig molecules called nectins and nectin-like proteins, which mediate cell-cell adhesion, cell migration, and serve as entry receptors for viruses. It has been recently shown that human NK cells recognize PVR through the receptor DNAM-1, which triggers NK cell stimulation in association with beta(2) integrin. In this study, we show that NK cells recognize PVR through an additional receptor, CD96, or T cell-activated increased late expression (Tactile). CD96 promotes NK cell adhesion to target cells expressing PVR, stimulates cytotoxicity of activated NK cells, and mediates acquisition of PVR from target cells. Thus, NK cells have evolved a dual receptor system that recognizes nectins and nectin-like molecules on target cells and mediates NK cell adhesion and triggering of effector functions. As PVR is highly expressed in certain tumors, this receptor system may be critical for NK cell recognition of tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034010     DOI: 10.4049/jimmunol.172.7.3994

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  138 in total

Review 1.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

2.  Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.

Authors:  Katharina F Stengel; Kristin Harden-Bowles; Xin Yu; Lionel Rouge; Jianping Yin; Laëtitia Comps-Agrar; Christian Wiesmann; J Fernando Bazan; Dan L Eaton; Jane L Grogan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

3.  Identification of endothelial cell junctional proteins and lymphocyte receptors involved in transendothelial migration of human effector memory CD4+ T cells.

Authors:  Thomas D Manes; Jordan S Pober
Journal:  J Immunol       Date:  2010-12-29       Impact factor: 5.422

4.  The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Authors:  Giulia Matusali; Marina Potestà; Angela Santoni; Cristina Cerboni; Margherita Doria
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

5.  CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.

Authors:  Naoki Hosen; Christopher Y Park; Naoya Tatsumi; Yusuke Oji; Haruo Sugiyama; Martin Gramatzki; Alan M Krensky; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

6.  Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Authors:  Véronique M Braud; Jérôme Biton; Etienne Becht; Samantha Knockaert; Audrey Mansuet-Lupo; Estelle Cosson; Diane Damotte; Marco Alifano; Pierre Validire; Fabienne Anjuère; Isabelle Cremer; Nicolas Girard; Dominique Gossot; Agathe Seguin-Givelet; Marie-Caroline Dieu-Nosjean; Claire Germain
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110

7.  CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Authors:  Amelia Roman Aguilera; Viviana P Lutzky; Deepak Mittal; Xian-Yang Li; Kimberley Stannard; Kazuyoshi Takeda; Günter Bernhardt; Michele W L Teng; William C Dougall; Mark J Smyth
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

Review 8.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

9.  Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Authors:  Heidi Harjunpää; Stephen J Blake; Elizabeth Ahern; Stacey Allen; Jing Liu; Juming Yan; Viviana Lutzky; Kazuyoshi Takeda; Amy Roman Aguilera; Camille Guillerey; Deepak Mittal; Xian Yang Li; William C Dougall; Mark J Smyth; Michele W L Teng
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

Review 10.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.